8-K: MSP Recovery Secures Up to $55M Loan Facility

MSP Recovery, Inc. has entered into a non-binding term sheet for a potential $55.0 million secured delayed draw term loan facility, including significant warrant issuance to the lender.

Summary

• MSP Recovery, Inc. and its subsidiaries (Co-Borrowers) signed a non-binding term sheet with a Lender for a potential first lien secured delayed draw term loan facility (the Facility).
• The Facility could provide up to $55.0 million in principal, structured in two tranches.
• Tranche A offers up to $10.0 million, with $5.0 million expected at closing and an additional $5.0 million available at the Lender's sole and absolute discretion prior to a specified contingency.
• Tranche B provides up to $45.0 million, available after the closing date, subject to the same contingency and the Lender's sole and absolute discretion.
• The loan would mature 36 months after closing, with two potential one-year extensions at the Lender's discretion.
• Obligations would be secured by a first-priority security interest in substantially all Co-Borrowers' assets, subject to inter-creditor arrangements.
• In connection with advances, the Company would issue warrants to the Lender to purchase Class A common stock at an exercise price of $0.01 per share, with a ten-year term.
• Warrant coverage ranges from 3.0% per $1.0 million drawn under initial Tranche A to 0.35% per $1.0 million drawn under later Tranche B, potentially reaching approximately 46.0% of fully diluted equity if the Facility is fully drawn.
• The Term Sheet also contemplates the Lender pursuing additional assignor claim rights and working with the Company to expand its portfolio or provide servicing rights.
• Key provisions include customary fees, financial reporting, Lender oversight, potential appointment of a Chief Restructuring Officer, and a voting trust arrangement for certain existing shareholders.
• The agreement is generally non-binding and subject to definitive documentation, due diligence, and customary closing conditions, with shareholder approval potentially required for certain aspects under Nasdaq rules.

Sentiment

Score: 4

Explanation: The potential for significant capital infusion is positive, but the non-binding nature, substantial dilution, first-priority security, and the potential for a Chief Restructuring Officer and voting trust arrangement indicate significant financial challenges and a high cost of capital, leading to a cautious sentiment.

Positives

• Potential access to up to $55.0 million in capital, which could significantly improve liquidity and fund operations.
• The Lender is committed to pursuing additional assignor claim rights and expanding the Company's portfolio of assigned claims or providing servicing rights, indicating a strategic partnership beyond just financing.
• The facility offers potential extensions, providing flexibility in repayment.

Negatives

• The Term Sheet is generally non-binding, meaning the financing is not guaranteed and definitive agreements may not be reached.
• Significant dilution risk for existing shareholders due to warrant issuance, potentially up to 46.0% of fully diluted equity if the facility is fully drawn.
• The Lender will have substantial oversight and approval rights, potentially including the appointment of a Chief Restructuring Officer, which suggests financial distress or significant operational changes.
• A voting trust arrangement for certain existing shareholders indicates a potential shift in control or influence.
• The loan is secured by a first-priority security interest in substantially all assets, limiting future financing options and increasing risk for unsecured creditors.
• Shareholder approval may be required for certain credit extensions and warrant issuances, introducing uncertainty and potential delays.

Risks

• The parties may not negotiate or execute definitive agreements on the terms contemplated by the Term Sheet or at all.
• The closing of any financing remains subject to completion of due diligence, internal approvals, and the satisfaction of other customary conditions.
• Shareholder approval may not be obtained for certain extensions of credit and warrant issuances.
• Even if consummated, the financing may not provide the anticipated benefits to the Company.
• Other risks and uncertainties described in the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2024, filed on April 16, 2025, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The Company anticipates that the proposed financing transaction, if consummated, could impact its capital structure and operations. However, the realization of this financing is subject to significant contingencies, including the negotiation of definitive agreements, completion of due diligence, and potential shareholder approval, and there is no certainty that the financing will close or provide the anticipated benefits.

Management Comments

• The Company believes that it has a reasonable basis for each forward-looking statement contained in this Current Report, though these statements are based on a combination of facts and factors currently known and its projections of the future, about which it cannot be certain.

Industry Context

This potential financing agreement for MSP Recovery, a company focused on healthcare claims recovery, highlights the ongoing need for capital in specialized healthcare services, particularly for companies involved in complex subrogation and claims management. The inclusion of a Chief Restructuring Officer and significant lender oversight suggests a challenging financial environment, potentially reflecting broader pressures on companies with unique business models or those undergoing significant operational transitions within the healthcare recovery sector.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Significant potential dilution (up to 46.0% fully diluted) due to warrant issuance. Potential for altered voting power through a voting trust arrangement. Uncertainty regarding the closing of the financing could impact share price.
• Creditors: Existing creditors may be impacted by the first-priority security interest granted to the new Lender, potentially subordinating their claims. Inter-creditor arrangements would define this.
• Management/Employees: Potential appointment of a Chief Restructuring Officer suggests increased scrutiny and potential operational changes, which could affect management roles and employee morale.
• Customers/Suppliers: The financing, if secured, could provide stability, ensuring continued operations and ability to meet obligations. The Lender's commitment to expanding claims could lead to more business.

Next Steps

• Negotiation and execution of definitive loan agreements.
• Completion of due diligence by the Lender.
• Satisfaction of customary closing conditions.
• Potential shareholder approval for certain credit extensions and warrant issuances.
• Lender pursuing acquisition of additional assignor claim rights and working with the Company to expand its portfolio or provide servicing rights.

Key Dates

Recommendation

While the potential $55.0 million financing offers a crucial lifeline for MSP Recovery, addressing immediate liquidity concerns, the terms are highly dilutive (up to 46.0% fully diluted equity) and come with significant lender control, including the potential for a Chief Restructuring Officer and a voting trust. The non-binding nature of the term sheet introduces substantial uncertainty regarding the actual closing of the facility. Investors should hold to monitor the progression of definitive agreements and assess the final terms, as the high cost of capital and governance implications could offset the benefits of the capital infusion. The strategic commitment from the lender to expand claims is a positive, but the overall risk profile remains elevated.

Keywords

MSP Recovery, MSPR, 8-K, Term Loan, Secured Financing, Warrants, Dilution, Capital Raise, Healthcare Claims, Subrogation, Chief Restructuring Officer, Nasdaq